Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 12:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 354 matching trials from the live ClinicalTrials.gov search.
Conditions
Uveitis
Interventions
Placebo, Dose 1 gevokizumab, Dose 2 gevokizumab
Drug
Lead sponsor
XOMA (US) LLC
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
52
States / cities
Chandler, Arizona • Phoenix, Arizona • Beverly Hills, California + 49 more
Conditions
Allergic Conjunctivitis
Interventions
Vehicle, Brimonidine Tartrate 0.01%, Brimonidine Tartrate 0.025%, Oxymetazoline HCl 0.025%
Drug
Lead sponsor
Eye Therapies, LLC
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Andover, Massachusetts
Conditions
Cataracts, Inflammation
Interventions
Difluprednate ophthalmic emulsion, 0.05%, Prednisolone acetate ophthalmic suspension, 1.0%
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
Up to 3 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Conditions
Burn Injury, Chronic Pain
Interventions
Ergocalciferol, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Obstructive Sleep Apnea (OSA)
Interventions
Positive airway pressure (PAP) therapy, Sleep dental device, Atomoxetine-oxybutynin
Device · Drug
Lead sponsor
Sairam Parthasarathy
Other
Eligibility
18 Years and older
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
4
States / cities
Tucson, Arizona • Redwood City, California • Miami, Florida + 1 more
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Mechanisms of Hypoglycemia in Patients Without Diabetes

NCT04428723
Conditions
Hypoglycemia
Interventions
Entry of demographic and medical history data into a deidentified database, Blood sample for DNA analysis, Stool sample for microbiome analysis, Mixed meal tolerance test, Continuous glucose monitoring, activity monitor
Other · Genetic · Diagnostic Test
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy

NCT04692688
Conditions
Diabetic Retinopathy, Diabetic Macular Edema, NPDR - Non Proliferative Diabetic Retinopathy, PDR - Proliferative Diabetic Retinopathy
Interventions
APX3330, Placebo
Drug
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
24
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 20 more
Completed Not applicable Interventional Results available

Estimating Apnea Phenotypes From Polysomnography: Oxygen

NCT01751971
Conditions
Sleep Apnea
Interventions
Inspired oxygen (40%), Sham
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
20 Years to 79 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Wet Macular Degeneration
Interventions
Faricimab, Aflibercept, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
41
States / cities
Phoenix, Arizona • Mountain View, California • Sacramento, California + 36 more
Conditions
Dry Eye
Interventions
EBI-005, Placebo
Drug
Lead sponsor
Eleven Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Birmingham, Alabama • Newport Beach, California • Hamden, Connecticut + 9 more
Conditions
Non-infectious Anterior Uveitis, Uveitic Glaucoma
Interventions
TRS01, FDA approved steroid eye drop (masked)
Drug
Lead sponsor
Tarsier Pharma
Industry
Eligibility
0 Years to 75 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
19
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 14 more
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
Verteporfin Photodynamic Therapy, Ranibizumab, Verteporfin Placebo, Ranibizumab Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
36
States / cities
Tucson, Arizona • Beverly Hills, California • Oakland, California + 33 more
Conditions
Spinal Cord Injuries
Interventions
Acute Intermitted Hypoxia, Massed Practise, Rapael Glove
Other · Procedure
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 75 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
3
States / cities
Chicago, Illinois • East Hanover, New Jersey
Conditions
Wet Macular Degeneration
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
50 Years and older
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
59
States / cities
Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 53 more
Completed Phase 2 Interventional Results available

ADVM-022 Intravitreal Gene Therapy for DME

NCT04418427
Conditions
Diabetic Macular Edema, Diabetic Retinopathy
Interventions
6E11 vg/eye of ADVM-022, 2E11 vg/eye of ADVM-022, Aflibercept
Biological
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 10 more
Conditions
Infantile Nystagmus Syndrome
Interventions
topical brinzolamide 1% in 5mL ophthalmic medication, Placebo in 5 mL dispenser
Drug
Lead sponsor
Akron Children's Hospital
Other
Eligibility
12 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Akron, Ohio
Conditions
Allergic Conjunctivitis
Interventions
PRT-2761 0.5%, PRT-2761 1%, Patanol, Pred-forte, PRT-2761 0%
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Andover, Massachusetts
Conditions
Dry Age-related Macular Degeneration, Geographic Atrophy
Interventions
Surgical implantation of the CPCB-RPE1 implant
Device
Lead sponsor
Regenerative Patch Technologies, LLC
Industry
Eligibility
55 Years to 90 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2040
U.S. locations
5
States / cities
Huntington Beach, California • Los Angeles, California • Lemont, Illinois + 2 more
Conditions
Postoperative Ocular Inflammation, Postoperative Ocular Pain
Interventions
Sham (No Treatment), TRIESENCE (triamcinolone acetonide injectable suspension)
Procedure · Drug
Lead sponsor
Harrow Inc
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Conditions
Dry Eye Disease
Interventions
Lifitegrast, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
41
States / cities
Birmingham, Alabama • Chandler, Arizona • Artesia, California + 33 more
Conditions
Diabetic Macular Edema (DME)
Interventions
UBX1325, Sham
Drug · Other
Lead sponsor
Unity Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
19
States / cities
Phoenix, Arizona • Bakersfield, California • Encino, California + 15 more
Conditions
Respiratory Distress Syndrome, Adult, Ventilator-Induced Lung Injury, Neurocognitive Dysfunction, Quality of Life, Respiration Disorders
Interventions
Ventilation Inhomogeneity, Diaphragm Ultrasound, Respiratory Inductance Plethysmography, Spirometry, Functional Residual Capacity, MIP/MEP, 6 minute walk test, Neurocognitive Testing, Emotional Health Assessment, Health Related Quality of Life, Functional Status, Respiratory Status Questionnaire
Diagnostic Test
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
1 Month to 18 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Proliferative Diabetic Retinopathy
Interventions
emixustat hydrochloride, Placebo
Drug · Other
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Arcadia, California
Conditions
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Interventions
Ixo-vec, Aflibercept
Genetic · Drug
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
75
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 67 more